Eledon Pharma Q1 net loss $9.9M; ALS topline data expected June 2022

Eledon Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.69

Net loss $9.9M ($0.69/diluted share) vs $8.5M ($0.57) in Q1 2021.
Cash $76.7M as of March 31, 2022, down from $84.8M; runway into 2024.
Phase 2a ALS trial fully enrolled; topline data anticipated in June 2022.
First patient dosed in Phase 2a IgA Nephropathy trial; initial data late 2022.
Non-human primate study of tegoprubart monotherapy in kidney allograft rejection completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.